Beta Drugs Limited submitted financial results for the period ended March 31, 2024, with consolidated revenues growing 30.2% to Rs 296 crores, EBITDA at Rs 61.4 crores, net profit up 19% to Rs 36.4 crores, and guidance for FY 25 expecting revenue increase of 25% to 30%